Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

Marie Thérèse Rubio1,2,3*, Maud D’Aveni-Piney1,2,3†, Myriam Labopin4,5,6,7, Rose-Marie Hamladji8, Miguel A. Sanz9, Didier Blaise10, Hakan Ozdogu11, Etienne Daguin deau12, Carlos Richard13, Stella Santarone14, Giuseppe Irrera15, Ibrahim Yakoub-Agha16, Moshe Yeshuron17, Jose L. Diez-Martin18, Mohamad Mohty4,5,6,7, Bipin N Savani4,19 and Arnon Nagler4,7,20

Abstract

Background: The impact of the use of anti-thymocyte globulin (ATG) in allogeneic stem cell transplantation performed with HLA-identical sibling donors following fludarabine and 4 days intravenous busulfan myeloablative conditioning regimen has been poorly explored.

Methods: We retrospectively analyzed 566 patients who underwent a first HLA-identical allogeneic stem cell transplantation with this conditioning regimen for acute myeloid leukemia in first complete remission between 2006 and 2013 and compared the outcomes of 145 (25.6%) patients who received ATG (ATG group) to 421 (74.4%) who did not (no-ATG group). The Kaplan-Meier estimator, the cumulative incidence function, and Cox proportional hazards regression models were used where appropriate.

Results: Patients in the ATG group were older, received more frequently peripheral blood stem cell grafts from older donors, and were transplanted more recently. With a median follow-up of 19 months, patients in the ATG group had reduced 2-year cumulative incidence of chronic graft-versus-host disease (cGVHD) (31 vs. 52%, \( p = 0.0002 \)) and of its extensive form (8 vs. 26%, \( p < 0.0001 \)) but similar relapse incidence (22 vs. 27%, \( p = 0.23 \)) leading to improved GVHD and relapse-free survival (GRFS) (60 vs. 40%, \( p = 0.0001 \)). In multivariate analyses, the addition of ATG was independently associated with lower chronic GVHD (HR = 0.46, \( p = 0.0001 \)), improved leukemia-free survival (HR = 0.67, \( p = 0.027 \)) and overall survival (HR = 0.65, \( p = 0.027 \)), and GRFS (HR = 0.51, \( p = 4 \times 10^{-5} \)). Recipient age above 50 years was the only other factor associated with worse survivals.

(Continued on next page)
Conclusions: These results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant outcomes due to reduced incidence of chronic GVHD without increased relapse risk.

Keywords: Allogeneic stem cell transplantation, HLA-matched related donor, Acute myeloid leukemia, In vivo T cell depletion, Graft-versus-host disease, Relapse incidence, GRFS

Background

Allogeneic hematopoietic stem cell transplantation (allo-SCT) with myeloablative conditioning (MAC) regimen remains the treatment of choice for intermediate or poor-risk acute myeloid leukemia (AML) in first complete remission (CR1) [1]. The standard conditioning regimen including myeloablative dose of intravenous (iv) busulfan and cyclophosphamide is however associated with substantial toxicities in adults above 40 years of age [2]. The association of fludarabine to myeloablative dose of iv busulfan (Flu-ivBu4), developed in the past two decades, has been shown to preserve significant anti-leukemic activity with reduced toxicity mortality in both retrospective [3–8] and prospective randomized studies [9, 10], in particular, in adults above 40 years. This so-called reduced toxicity conditioning (RTC) regimen is therefore being widely used in allo-SCT for patients with AML in CR1.

The Flu-ivBu4 regimen is usually performed with peripheral blood stem cells (PBSC) to favor engraftment and enhance the graft-versus-leukemia (GVL) effect [11, 12]. However, use of PBSC from HLA-matched related (MRD) or unrelated (MUD) donors with MAC increases the risk of chronic graft-versus-host disease (cGVHD) [11–13]. Prospective randomized studies have shown that in vivo T cell depletion with anti-thymocyte globulin (ATG) reduces the incidence of GVHD without increasing the risk of relapse in allo-SCT performed with PBSC from MRD or MUD after conventional cyclophosphamide-based MAC regimens for AML [14–16]. These results raise the question of the impact of use of ATG in the Flu-ivBu4 RTC, in which the balance between the GVH and GVL effects of allo-SCT might be more sensitive to T cell depletion. Very scarce data exist on the potential effect of ATG in this transplant context. Russel et al. reported reduced non-relapse mortality (NRM) due to lower incidence of cGVHD in a retrospective study of patients transplanted with MRD after Flu-Bu-based MAC and ATG compared to conventional cyclophosphamide-based MAC without ATG but a trend towards higher relapse incidence [17]. A Korean study comparing the outcomes of 16 patients receiving Flu-ivBu for 3 or 4 days and ATG to 45 patients receiving the same type of conditioning without ATG for various hematological malignancies transplanted with MRD did not observe any benefit of adding ATG, with also concerns about its possible negative impact on relapse [18]. Heterogeneity in terms of conditioning between groups or of types of disease limits the interpretation of these data. With the objective to explore the impact of the use of ATG in the Flu-ivBu4 RTC, we chose to retrospectively analyze a cohort of 566 adult patients given hematopoietic stem cells from HLA-identical sibling donors for AML in CR1 following Flu-ivBu4 conditioning regimen. In this homogeneous cohort of patients, we compared post-transplant outcomes of 145 of those who received ATG for GVHD prophylaxis to the 421 patients who did not.

Methods

Study design and data collection

This is a retrospective multicenter analysis using the data set of the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT) group registry. The EBMT is a voluntary working group of more than 500 transplant centers that are required to report all consecutive stem cell transplantations and follow-ups once a year. Audits are routinely performed to determine the accuracy of the data. The study was planned and approved by the ALWP of the EBMT. In addition, the study protocol was approved by the institutional review board at each site and complied with country-specific regulatory requirements. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Since 1990, patients provide informed consent authorizing the use of their personal information for research purposes. Eligibility criteria for this analysis included adult patients above 18 years of age with AML who underwent a first allo-SCT from an HLA-matched related donor following fludarabine and 4 days of intravenous busulfan (Flu-ivBu4) regimen between 2006 and 2013. Exclusion criteria were previous allogeneic or cord blood transplantation and ex vivo T cell-depleted stem cell graft. Variables collected included recipient and donor characteristics (age, gender, CMV serostatus), disease characteristics and status at transplant, year of transplantation and interval from diagnosis to transplantation, transplant-related factors including conditioning regimen, use and dose of thymoglobulin as pre-transplant in vivo T cell depletion, stem cell source (bone marrow (BM) or peripheral blood (PB)),...
post-transplant GVHD prophylaxis. GVHD prophylaxis regimens were dependent on centers’ protocols. Grading of acute GVHD was performed using established criteria [19]. Chronic GVHD was classified as limited or extensive according to published criteria [20]. For the purpose of this study, all necessary data were collected according to the EBMT guidelines, using the EBMT minimum essential data forms. The list of institutions reporting data included in this study is provided in the supplemental data (Additional file 1: Table S1).

Statistical analysis

Study end points were engraftment, incidences and severity of acute and chronic GVHD, incidence of primary disease relapse (RI), NRM, leukemia-free survival (LFS), overall survival (OS), and GVHD and relapse-free survival (GRFS). Start time was date of transplant for all end points. LFS was defined as survival without relapse or progression, NRM as death without relapse/progression, and GRFS as survival with no evidence of relapse/progression, grade III to IV acute graft-versus-host disease (aGVHD), or severe cGVHD as defined by Ruggeri et al. for registry-based studies [21]. Cumulative incidence functions (CIF) were used to estimate RI and NRM in a competing risk setting, because death and relapse compete with each other. For estimating the cumulative incidence of chronic GVHD, we considered relapse and death to be competing events. Groups were compared by the chi-square method for qualitative variables, whereas the Mann-Whitney test was applied for continuous parameters. Univariate comparisons were done using the log-rank test for OS, LFS, and GRFS and the Gray’s test for RI, NRM, and GVHD cumulative incidences. Multivariate analyses were performed using Cox proportional hazards model for all end points. Factors differing in terms of distribution between the groups and all factors known as potentially risk factors were included in the final model. In order to test for a center effect, we introduced a random effect or frailty for each center into the model [22]. All tests were two-sided. The type I error rate was fixed at 0.05 for the determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS 22.0 (IBM Corp., Armonk, NY, USA) and R 3.2.3 software packages (R Development Core Team, Vienna, Austria).

Results

Patient, transplant, and disease characteristics

Between 2006 and 2013, 566 patients with AML transplanted with a sibling donor following a Flu-ivBu4 myeloablative conditioning regimen with or without ATG were included in the study. Patient and disease characteristics are summarized in Table 1. Among the total population of patients, 421 (74.4%) did not receive ATG within the conditioning regimen (no-ATG group), while 145 (25.6%) received ATG (ATG group). Thymoglobulin was the main ATG brand used (95.2%). Median dose of thymoglobulin was 5 mg/kg (range, 2.5–15.8), and a majority of patients (73.7%) received a total dose below 6 mg/kg. Apart from ATG, GVHD prophylaxis was mainly based on the association of cyclosporine (CsA) and methotrexate (MTX) in the no-ATG group (88.4%), while most of the patients in the ATG group received CsA alone (29%) or CsA and MTX (40%). The choice of GVHD prophylaxis was dependent on the centers’ protocols.

In comparison to the no-ATG group, patients in the ATG group were older (median age of 48.8 vs. 43.7 years, \( p = 0.002 \)), had been transplanted more recently (median year of transplantation 2012 vs. 2011, \( p < 10^{-5} \)), with older donors (median age of 47 vs. 41 years, \( p = 0.003 \)), and were more frequently transplanted with PBSC graft (93 vs. 80%, \( p < 10^{-5} \)) for secondary AML (12 vs. 7%, \( p = 0.05 \)). There was no difference in terms of cytogenetic risk between the two groups in patients with available cytogenetics. Significantly higher proportions of CMV seropositive patients were transplanted in the no-ATG group (87 vs. 74%, \( p < 10^{-4} \)) resulting in different distributions of transplant CMV risk with increased low risk in the ATG group (15.5 vs. 8%, \( p = 0.008 \)) (Table 1).

Impact of ATG on engraftment and GVHD

Engraftment and incidences of acute and chronic GVHD are shown in Table 2. There was no difference in terms of engraftment between the no-ATG and ATG groups (98.6 and 100%, respectively, \( p = 0.15 \)). Median time for absolute nuclear cells (ANC) > 0.5 × 10⁹/L was longer in the no-ATG group (15 and 14 days, respectively, \( p = 0.001 \)) (Table 2).

In univariate analysis, we did not observe any impact of the use of ATG on the incidences of grade II–IV and grade III–IV aGVHD. Day 100 cumulative incidences of grade II–IV and III–IV aGVHD were similar between the no-ATG and ATG groups (21.8 vs. 15.3%, \( p = 0.10 \) and 7.7 vs. 4.4%, \( p = 0.19 \), respectively) (Table 2). By contrast, 2-year incidences of overall and extensive chronic GVHD were significantly reduced in the ATG group in comparison to the no-ATG group (30.8 vs. 52% for overall cGVHD, \( p = 0.0002 \) and 7.6 vs. 26.3% for extensive cGVHD, \( p < 10^{-5} \)) (Tables 2 and 3 and Fig. 1). As shown in Table 4, GVHD-related deaths represented 22.2% (\( n = 32 \)) and 17.1% (\( n = 6 \)) of all causes of death in the no-ATG and ATG groups, respectively.

In multivariate analyses, the use of ATG was associated with a reduced risk of chronic GVHD development (hazard ratio (HR) = 0.46, 95% CI, 0.31–0.68; \( p = 0.0001 \)) (Table 5). Factors associated with an increased risk of developing chronic GVHD were secondary AML (HR = 1.68, 95% CI, 1.04–2.72; \( p = 0.033 \)) and the use of a female
| Patient characteristics                  | No-ATG | ATG      | p value |
|-----------------------------------------|--------|---------|---------|
| Number of patients                      | 421    | 145     | 0.002   |
| Recipient age at SCT (years, range)     | 43.7 (18–68) | 48.8 (20–69) | 0.24 |
| Recipient gender, n (%)                 |        |         |         |
| Male                                    | 215 (51.3%) | 82 (56.9%) | 0.24 |
| Female                                  | 204 (48.7%) | 62 (43.1%) | 0.24 |
| Year of SCT (median), year (%)          | 2011 (2006–2013) | 2012 (2006–2013) | <10<sup>−5</sup> |
| Interval from diagnosis to SCT (median days) | 156    | 156     | 0.79    |
| Median follow-up * (months, range)      | 16 (1.5–93) | 21 (1–106) | 0.81 |
| Donor age (years, range)                | 41 (8–70) | 47 (10–65) | 0.003   |
| Donor gender, n (%)                     |        |         |         |
| Male                                    | 236 (56.3%) | 70 (48.6%) | 0.11 |
| Female                                  | 183 (43.7%) | 74 (51.4%) | 0.11 |
| Female donor to male recipient, n (%)   | 96 (23%) | 44 (30.9%) | 0.06 |
| Diagnosis, n (%)                        |        |         | 0.05    |
| De novo AML                             | 391 (92.9%) | 127 (87.6%) | 0.05 |
| Secondary AML                           | 30 (7.1%) | 18 (12.4%) | 0.05 |
| Cytogenetics in de novo AML, n (% of available data) | 0.60 | 0.60 |
| Good                                    | 18 (16.2%) | 6 (9%)    |         |
| Intermediate                            | 76 (68.5%) | 50 (74.6%) |         |
| Poor                                    | 17 (15.3%) | 11 (16.4%) |         |
| Not available/failed                    | 280     | 60      |         |
| Source of SC, n (%)                     |        |         | <10<sup>−4</sup> |
| BM                                      | 84 (20%) | 10 (6.9%) |         |
| PB                                      | 337 (80%) | 135 (93.1%) |         |
| In vivo T cell depletion, n (%)          |        |         |         |
| Thymoglobuline                          | 0       | 138 (95.2%) |         |
| ATG Fresenius                           | 4 (2.8%) | 6 (9%)    |         |
| Missing brand of ATG                    | 3 (2%)  | 3 (2%)   |         |
| Mean dose of thymoglobuline (mg/kg) (range) | 5 (2.5–15.8) | 98 (73.7%) |         |
| Thymo ≤ 6 mg/kg                         | 35 (26.3%) | 35 (26.3%) |         |
| Thymo > 6 mg/kg                         | 35 (26.3%) | 35 (26.3%) |         |
| Unknown dose of thymoglobuline          | 12      | 12      |         |
| Post-transplant GVHD prophylaxis         |        |         | <10<sup>−4</sup> |
| CsA                                     | 4 (1%)  | 42 (29%) |         |
| CsA + MTX                               | 372 (88.4%) | 57 (39.3%) |         |
| CsA/FK 506 + MMF                        | 35 (8.3%) | 17 (11.7%) |         |
| Other                                   | 10 (2.4%) | 29 (20%) |         |
| Patient positive CMV serology, n (%)    | 362 (87%) | 107 (74.3%) | <10<sup>−4</sup> |
| Donor positive CMV serology, n (%)      | 330 (80.1%) | 104 (72.7%) | 0.07 |
| CMV risk, n (%)                         |        |         | 0.008   |
| Low                                     | 33 (8%)  | 22 (15.5%) |         |
| Intermediate                            | 328 (77.9%) | 103 (71%) |         |
| High                                    | 49 (12%) | 17 (12%) |         |

CMV risk low = negative recipient and donor serology, high positive recipient and negative donor serology, intermediate: all other combinations
AML acute myeloid leukemia, ATG anti-thymocyte globulin, BM bone marrow, CMV cytomegalovirus, CsA cyclosporine A, MMF mycophenolate mofetil, MTX methotrexate, PB peripheral blood, SC stem cells, SCT stem cell transplantation
*For alive patients
Table 2 Engraftment and GVHD

|                | No-ATG | ATG | p value |
|----------------|--------|-----|---------|
| Total number of patients | 421    | 145 |         |
| Engraftment, n (%) | 411 (98.6%) | 145 (100%) | 0.15 |
| No engraftment, n (%) | 6 (1.4%) | 0 (0%) |         |
| Missing, n | 5 | 0 |         |
| Median time ANC > 0.5 G/L (days, range) | 15 (5–45) | 14 (5–28) | 0.001 |

Acute GVHD,
- Grade 0–I, n (%) | 315 (78.2%) | 116 (84.7%) | 0.10 |
- Grade II–IV, n (%) | 88 (21.8%) | 21 (15.3%) |         |
- Grade III–IV, n (%) | 31 (7.7%) | 6 (4.4%) | 0.19 |
- Missing, n | 5 | 3 |         |

Chronic GVHD*
- All grades | 52% (46–57.7) | 30.8% (22.3–39.8) | 0.00026 |
- Extensive | 26.3% (21.2–31.6) | 7.6% (3.5–13.7) | 4.7 × 10^{-5} |
- Limited, n | 71 | 26 |         |
- Extensive; n | 77 | 8 |         |
- Missing, n | 117 | 28 |         |

ATG anti-thymocyte globulin, GVHD graft-versus-host disease
*Two-year cumulative incidence

donor for a male recipient (HR = 1.75, 95% CI, 1.27–2.43; p = 0.001). We observed a center effect on the incidence of cGVHD (p = 0.0007) (Table 5).

Toxicity and NRM
The median follow-up of the entire cohort of 19 months (range, 1–106) was similar in both no-ATG (16 months) and ATG groups (21 months) (Table 1). Two-year NRM for the entire cohort was 15.5% (95% CI, 12.3–19.1). In univariate analysis, 2-year cumulative incidence of NRM was no different between the no-ATG (17.3%; 95% CI, 13.3–21.7) and the ATG (10.7%; 95% CI, 7.7–14.2) groups (p = 0.149). (Table 3 and Fig. 2a).

Apart from GVHD, the main other causes of death from NRM in the no-ATG and ATG groups were infections (23 patients and 5 patients (16 and 14.3% of all deaths), respectively) and veno-occlusive disease (3 patients in each group (3.5 and 8.6% of all deaths), respectively) (Table 4).

In multivariate analyses, recipient age above 50 years was associated with an increased risk of NRM (HR = 1.83, 95% CI, 1.14–2.94; p = 0.012) and we observed a center effect on the incidence of NRM (p = 0.047). Although not significant, there was a trend for reduced NRM in patients receiving ATG (HR = 0.59, 95% CI, 0.32–1.09; p = 0.094) (Table 5).

Use of ATG had no impact on relapse incidence
Two-year cumulative incidence of relapse in the entire cohort of patients was 25.9% (95% CI, 21.8–30.1) and represented the main cause of death in the two groups of patients: 53.4% of all causes of death in the no-ATG and 54.5% of those of the ATG groups (Table 4). In univariate analysis, the use of ATG had no impact on the 2-year incidence of relapse, which occurred in 27.2% (95% CI, 22.4–32.1) of the patients in the no-ATG group and in 22.5% (95% CI, 15.1–30.8) of those in the ATG group (p = 0.226) (Table 3 and Fig. 2b). The absence of the impact of ATG on relapse risk was confirmed in multivariate analyses (HR = 0.72, 95% CI, 0.46–1.12; p = 0.149) (Table 5). No significant factor was associated with the risk of relapse in this study, although older age (>50 years) showed a trend to an increased risk (HR = 1.39, 95% CI, 0.96–2.00; p = 0.083).

Use of ATG improved transplant survivals including GRFS
At 2 years, LFS and OS for in the entire cohort of patients were 58.4% (95% CI, 53.7–63.2) and 62.2% (95% CI, 57.4–67), respectively. In univariate analysis, 2-year LFS and OS were improved in the ATG group (66.8%; 95% CI, 58.1–75.6 and 71.8%; 95% CI, 63.4–80.2, respectively) in comparison to the no-ATG group (55.4%; 95% CI, 49.8–61 and 58.9%; 95% CI, 53.2–64.6, respectively) (p = 0.044 and 0.049, respectively) (Table 3 and Fig. 2c, d). The beneficial impact of ATG on LFS and OS was confirmed in multivariate analyses (HR = 0.67, 95% CI, 0.46–0.95, p = 0.027 for LFS and HR = 0.65; 95% CI, 0.44–0.95, p = 0.027 for OS) (Table 5). The only other factor that also impacted transplant survivals was recipient older age (>50 years) resulting in impaired LFS (HR = 1.53, 95% CI, 1.15–2.05, p = 0.004) and worse OS (HR = 1.42, 95% CI, 1.04–1.93, p = 0.026) (Table 5).

Table 3 Post-transplant 2-year outcomes

|                | NRM | RI | Extensive GVHD | GRFS | LFS | OS |
|----------------|-----|----|----------------|------|-----|----|
| No-ATG         | 17.3% [13.3–21.7] | 27.2% [22.4–32.1] | 26.3% [21.2–31.6] | 39.6% [34–45.1] | 55.4% [49.8–61] | 58.9% [53.2–64.6] |
| ATG            | 10.7% [7.7–14.2] | 22.5% [15.1–30.8] | 7.6% [3.5–13.7] | 60.1% [51–69.3] | 66.8% [58.1–75.6] | 71.8% [63.4–80.2] |
| p value        | 0.149 | 0.226 | 4.7 × 10^{-5} | 0.00016 | 0.044 | 0.049 |

ATG anti-thymocyte globulin, GRFS GVHD and relapse-free survival, LFS leukemia-free survival, NRM non-relapse mortality, OS overall survival, RI relapse incidence.
Two-year overall GRFS was 45.0% (95% CI, 40.1–49.8). In univariate analysis, patients of the ATG group had improved 2-year GRFS (60.1%, 95% CI, 51–69.3) compared to those of the no-ATG group (39.6%, 95% CI, 34–45.1) \((p = 0.00016)\) (Table 3 and Fig. 3). Use of ATG was significantly associated with improved GRFS in multivariate analyses \((HR = 0.51, 95\% CI, 0.37–0.70, p = 4 \times 10^{-5})\) (Table 5), while use of a female donor for a male recipient and recipient older age (>50 years) were associated with worse GRFS \((HR = 1.62, 95\% CI, 1.24–2.11, p = 0.0004)\) and \((HR = 1.32, 95\% CI, 1.02–1.71, p = 0.037)\) (Table 5).

**Discussion**

The main challenge of allo-SCT in AML and other hematological malignancies remains to limit organ life-threatening toxicity while preserving the GVL effect and patients’ quality of life by avoiding severe chronic GVHD. The GVHD and relapse-free survival composite end point is becoming an important end point to improve in allo-SCT \([21, 23]\). In this objective, while improvements in terms of tolerability of the transplant process have been shown in the last two decades by the development of reduced intensity and toxicity conditioning regimens and by improvement of supportive care including management of infections \([24]\), the increased use of PBSC grafts, reaching 70% of stem cell grafts used in Europe nowadays \([25]\), is also associated with higher incidence of severe cGVHD even with HLA-identical sibling donors \([11, 12, 26]\), thus potentially impairing GRFS. The Flu-ivBu4 RTC associated with PBSC graft has been reported as effective than conventional Bu-cyclophosphamide MAC regimen but with reduced short- and long-term non-relapse mortality in AML patients transplanted in CR1 with an HLA 10/10-matched related or unrelated donor \([8–10]\). However, the incidence of chronic GVHD with PBSC (80%) grafts from HLA-identical sibling donors, following such RTC in the absence of ATG, remains high with 68% overall cGVHD and 42% extensive cGVHD incidences at 4 years post-transplant reported recently by the Spanish Cooperative Transplant Group \([7]\). The current study was limited to AML in CR1 transplanted with HLA-identical donors to reduce bias due to donor type and disease status on transplant outcomes. As reported in other contexts of allo-SCT \([14, 16, 17, 27–30]\), we confirm in the present study that the addition of intermediate dose of thymoglobulin (median, 5 mg/kg) significantly reduces, after adjustment to other factors, the risk of developing cGVHD \((Cox\ HR = 0.46, p = 0.0001)\). Compared to patients not receiving ATG, those transplanted with ATG, despite having received more frequently PBSC, had a reduction of 2 years of cumulative incidence of the overall cGVHD from 52 to 31% \((p = 0.00026)\) and that of extensive cGVHD from 26 to 8% \((p < 10^{-4})\). Such reduction of cGVHD incidence was not associated with reduced anti-leukemic control since use of ATG did not impact

**Table 4 Causes of death**

|               | No-ATG     | ATG        |
|---------------|------------|------------|
| N             | 144        | 35         |
| Relapse       | 77 (53.5%) | 19 (54.3%) |
| GVHD          | 32 (22.2%) | 6 (17.1%)  |
| Infection     | 23 (16%)   | 5 (14.3%)  |
| VOD           | 5 (3.5%)   | 3 (8.6%)   |
| Idiopathic pneumonia | 2 (1.4%) | 0 (0%)  |
| Hemorrhage    | 2 (1.4%)   | 0 (0%)     |
| Other SCT-related | 3 (2.1%) | 2 (5.7%) |

ATG anti-thymocyte globulin, GVHD graft-versus-host disease, SCT stem cell transplantation, VOD veno-occlusive disease
|                          | Chronic GVHD |                 | NRM |                 | Relapse |                 | LFS |                 | OS |                 | GRFS |                 |
|--------------------------|--------------|-----------------|-----|-----------------|---------|-----------------|-----|-----------------|----|-----------------|------|-----------------|
| **p value**              | **OR (95% CI)** | **p value**     | **HR (95% CI)** | **p value** | **HR (95% CI)** | **p value** | **HR (95% CI)** | **p value** | **HR (95% CI)** | **p value** | **HR (95% CI)** |
| In vivo T cell depletion | 0.0001       | 0.46 (0.31–0.68)| 0.004 | 0.59 (0.32–1.09)| 0.149  | 0.72 (0.46–1.12)| 0.027 | 0.67 (0.46–0.95)| 0.027 | 0.65 (0.44–0.95)| 4 × 10\(^{-5}\) | 0.51 (0.37–0.70)|
| Age at SCT > 50 years    | 0.447        | 1.13 (0.82–1.57)| 0.012 | 1.83 (1.14–2.94)| 0.083  | 1.39 (0.96–2.00)| 0.004 | 1.53 (1.15–2.05)| 0.026 | 1.42 (1.04–1.93)| 0.037 | 1.32 (1.02–1.71)|
| Interval diag. to SCT\(a\) | 0.465        | 1.05 (0.91–1.22)| 0.209 | 1.00 (1.00–1.00)| 0.974  | 1.00 (1.00–1.00)| 0.461 | 1.00 (1.00–1.00)| 0.410 | 1.00 (1.00–1.00)| 0.717 | 1.00 (1.00–1.00)|
| Year of SCT              | 0.929        | 1.00 (1.00–1.00)| 0.894 | 0.99 (0.87–1.30)| 0.862  | 1.01 (0.91–1.12)| 0.960 | 1.00 (0.92–1.09)| 0.558 | 0.98 (0.90–1.06)| 0.522 | 0.98 (0.91–1.05)|
| Secondary AML            | 0.033        | 1.68 (1.04–2.72)| 0.232 | 1.55 (0.76–3.19)| 0.434  | 1.26 (0.71–2.26)| 0.192 | 1.35 (0.86–2.12)| 0.163 | 1.40 (0.87–2.25)| 0.058 | 1.47 (0.99–2.18)|
| Female D to male R       | 0.001        | 1.75 (1.27–2.43)| 0.669 | 1.12 (0.66–1.90)| 0.319  | 1.22 (0.82–1.82)| 0.306 | 1.18 (0.86–1.62)| 0.253 | 1.21 (0.87–1.69)| 0.0004| 1.62 (1.24–2.11)|
| R CMV seropositivity     | 0.231        | 1.32 (0.84–2.09)| 0.851 | 0.93 (0.46–1.90)| 0.733  | 0.91 (0.55–1.53)| 0.651 | 0.91 (0.60–1.38)| 0.456 | 0.85 (0.55–1.31)| 0.639 | 0.92 (0.64–1.32)|
| D CMV seropositivity     | 0.017        | 1.17 (0.81–1.68)| 0.241 | 1.49 (0.77–2.89)| 0.812  | 1.06 (0.67–1.68)| 0.358 | 1.20 (0.82–1.75)| 0.359 | 1.21 (0.81–1.80)| 0.832 | 1.04 (0.75–1.42)|
| Center (frailty variable)| 0.0007       | 0.047           | 0.211 | 0.917           | 0.913  | 0.154           |

AML acute myeloid leukemia, CMV cytomegalovirus, D donor, diag diagnosis, GRFS GVHD/relapse-free survival, GVHD graft-versus-host disease, LFS leukemia-free survival, NRM non-relapse mortality, OS overall survival, R recipient, SCT allogeneic stem cell transplantation

\(a\)Analyzed per 6-month interval
relapse incidence in this series of AML transplanted in CR1 in both univariate and multivariate analyses. Most patients had received a thymoglobulin dose of <6 mg/kg, so we could not analyze the impact of the ATG dose on outcomes. However, these results are in line with preserved GVL effect despite the addition of low or intermediate doses of ATG in the context of allo-SCT for AML performed with MRD and MUD following conventional MAC [31, 32] and RIC [29, 30, 33, 34], in contrast with increased risk of relapse with doses of thymoglobulin >10 mg/kg [28].

By contrast, as reported by others [15, 17, 30], we did not observe protective effect of such doses of ATG against acute GVHD. Actually, in the context of allo-SCT performed with PBSC from matched related or unrelated donors, use of low doses of ATG (2.5 mg/kg of thymoglobulin) was associated with an increased risk of aGVHD [34, 35]; a reduction of the incidence of aGVHD has been observed with thymoglobulin doses starting at 5 mg/kg, although higher doses (≥7.5 mg/kg of thymoglobulin) were associated with increased risk of mortality from infections and relapse in both MAC and RIC.
The optimal dose of thymoglobulin in both RIC and MAC seems therefore to be about 5 mg/kg. At such intermediate dose of ATG, as described by others [14, 15, 30, 37], we did not observe difference of infection-related mortality between the ATG and no-ATG groups, despite potential increased frequency of viral EBV reactivation manageable by viral load monitoring and preemptive use of rituximab [30, 37].

Altogether, our results show that the addition of intermediate dose of ATG to the Flu-ivBu4 RTC represents an independent factor associated with improved GRFS, as defined by Ruggeri et al. for registry-based studies [21], allowing a probability of being alive without disease and without significant cGVHD at 2 years after allo-SCT in 60% of the patients transplanted for AML in CR1 with a sibling donor, compared to 40% of those not receiving ATG. Although GRFS is not routinely analyzed up to now, a 2-year 60% GRFS compares favorably to 40% GRFS at 3 years reported after allo-SCT performed for AML transplanted in CR1 with HLA-identical sibling donors within the EBMT registry [21], and to 25% at 1 year reported with PBSC HLA-sibling donor allo-SCT by the Minnesota Group [23].

Use of ATG in our series appears also as an independent factor associated with improved LFS and OS, mainly due to reduced incidence of overall and extensive cGVHD leading to a trend towards increased late NRM in the absence of ATG. Although a center effect was observed in the incidence of cGVHD and NRM, possibly due to preferential used of ATG and of prophylactic donor lymphocyte infusion in some centers, we did not detect a center effect on LFS, OS, and GRFS. The only other factor associated with worse survivals was recipient age above 50 years, due to higher NRM, as reported by others with such conditioning regimen [7].

Conclusions
We recognize that this study has several limitations, mainly because of its retrospective aspect and that the reason for the choice of GVHD prophylaxis was not known but mainly dependent on the center’s protocols. However, the study was performed on a homogeneous cohort of AML patients transplanted in CR1 with HLA-identical sibling donors following a Flu-ivBu4 RTC. Despite these limitations, the results of this study suggest that, in this particular setting, an intermediate dose of ATG improves the composite end point severe GVHD and relapse-free survival by reducing the incidence of overall and chronic GVHD without affecting the long-term anti-leukemic effect. These results should be confirmed in a well-designed phase III randomized trial.
Additional file 1: Table S1. List of institutions reporting the patients’ data for the study. (DOCX 33 kb)

Abbreviations

aGvHD: Acute graft-versus-host disease; allo-SCT: Allogeneic hematopoietic stem cell transplantation; AML: Acute myeloid leukemia; ANC: Absolute nuclear cells; ATG: Anti-thymocyte globulin; BM: Bone marrow; cGvHD: Chronic graft-versus-host disease; CI: Cumulative incidence; CMV: Cytomegalovirus; CR: Complete remission; EBV: Epstein-Barr virus; Flu+Bu: Fludarabine and 4 days intravenous busulfan; GRFS: GvHD and relapse-free survival; GVL: Graft-versus-leukemia; HR: Hazard ratio; LFS: Leukemia-free survival; MAC: Myeloablative conditioning; MRD: Matched related donor; MUD: Matched unrelated donor; NRM: Non-relapse mortality; OS: Overall survival; PB: Peripheral blood; PBSC: Peripheral blood stem cells; RI: Relapse incidence; RTC: Reduced toxicity conditioning; VOD: Veno-occlusive disease

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

ML, MM, and AN had full access to all the data in the study (available upon data specific request).

Authors’ contributions

MTR, BNS, ML, and AN designed the research and/or analyzed data. RMH, MAS, DB, HO, ED, CRE, SS, GI, IYA, MY, and JLDLM provided the clinical data. MTR, MD, BNS, ML, and AN wrote the manuscript, and all authors approved the final version of the manuscript. A complete list of contributors, as well as members of the European Blood and Marrow Transplantation Group, appears on the online data supplement. MTR, MDP, BNS, MM, and AN had final responsibility for the decision to submit for publication.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study protocol was approved by the institutional review board at each site and complied with country-specific regulatory requirements. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients provide informed consent authorizing the use of their personal information for research purposes.

Author details

1Service d’Hématologie et de Médecine Interne, Hôpital Brabois, CHRU Nancy, Nancy, France. 2Institut d’Oncologie et de Rénovation, CNRS UMR 7365, Nancy, France. 3Université de Lorraine, Nancy, France. 4ALWP Office, Hôpital Saint Antoine, Paris, France. 5Service d’Hématologie et de Thérapie Cellulaire, Hôpital Saint Antoine, Paris, France. 6INSERM UMR 938, Paris, France. 7Université Pierre et Marie Curie, Paris, France. 8Service Hématologie Greffe de Moelle, Centre Pierre et Marie Curie, Alger, Algeria. 9Servicio de Hematologia, Hospital Universitario La Fe, Valencia, Spain. 10Programme de Transplantation et Thérapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France. 11Hematology Division, BMT Unit, Hematology Research Laboratory, Training and Medical, Baskent University Hospital, Adana, Turkey. 12Hôpital Jean Minjoz, Service d’Hématologie, Besancon, France. 13Servizio di Trapianti d’Organi, Ospedale Universitario di Modena, Modena, Italy. 14Servizio di Trapianto d’Organi, Ospedale Universitario di Modena, Modena, Italy. 15Hôpital HURiez UAM allo-CSH, CHRU, Lille, France. 16Service d’Hématologie et BMT Department, Bellinson Hospital, Petach-Tikva, Israel. 17Sección de Trasplante de Medula Osea, Hospital Gregorio Marañón, Madrid, Spain. 18Vanderbilt University Medical Center, Nashville, TN, USA. 19Division of Hematology, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Received: 4 October 2016 Accepted: 31 December 2016
Published online: 24 January 2017

References

1. Koreth J, Schlenk R, Kopeczy KJ, Honda S, Sierra J, Djulbegovic B, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61.
2. Cornelsen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenens SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):685–68.
3. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857–64.
4. Alatrasch G, de Lima M, Harnerschak N, Pelosini M, Wang X, Xiao L, et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011;17(10):1490–6.
5. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008;14(6):672–84.
6. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant. 2007;40(6):541–7.
7. De La Serna J, Sanz J, Bermudez A, Cabrero M, Serrano D, Vallejo C, et al. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. Bone Marrow Transplant. 2016;51(7):961–6.
8. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia. 2006;20(2):322–8.
9. Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol. 2013;6:15.
10. Ramdahl A, Grasi A, Masculi A, Bopchini C, Mico MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525–36.
11. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175–81.
12. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(24):5074–87.
13. Anasetti C, Logan BR, Lee SJ, Walker EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–96.
14. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.
15. Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antithymocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43–53.
16. Baciagalupo A, Lamparelli T, Barisone G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560–5.

17. Russell JA, Turner AR, Larrat L, Chaudhry A, Morris D, Brown C, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease a matched pair analysis. Biol Blood Marrow Transplant. 2007;13(3):299–306.

18. Ji YS, Lee MS, Min CW, Park SK, Kim SH, Yun J, et al. Does antithymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Korean J Intern Med. 2016;31(4):750–61.

19. Prazeporka D, Weidorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–8.

20. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–17.

21. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GVHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610–1.

22. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18(12):1489–500.

23. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brumstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333–8.

24. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):969–706.

25. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50(4):476–82.

26. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266–74.

27. Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204–17.

28. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102(2):470–6.

29. Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Caddock D, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(4):389–96.

30. Binkert L, Medinger M, Halter JP, Heim D, Gerull S, Holbro A, et al. Lower dose anti-thymocyte globulin for GVHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50(10):1331–6.

31. Mohty M, Labopin M, Baleere ML, Socie G, Milipied N, Tabrizi R, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia. 2010;24(11):1867–74.

32. Russell JA, Savid M, Balogh A, Turner AR, Larrat L, Chaudhry MA, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Blood Marrow Transplant. 2007;13(7):814–21.

33. Rubio MT, Labopin M, Blaise D, Socie G, Contreras RR, Chevaller P, et al. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2015;100(5):e683–9.

34. Devillier R, Crociolo R, Castagna L, Forst S, El Cheikh J, Faucher C, et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant. 2012;47(5):639–45.

35. Crociolo R, Esterni B, Castagna L, Forst S, El Cheikh J, Devillier R, et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer. 2013;119(5):986–92.

36. Baciagalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7.

37. Walker I, Panzarella T, Couban S, Couture F, Devins G, Eleyem M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–73.